Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond.
To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset.